Clinical Trials Browser

Phase 1/2 × Sarcoma × Magnetic Resonance Spectroscopy × Clear all

NCT05286801 2026-03-18

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase 1/2 Active not recruiting

Chordoma, Sarcoma, Rhabdoid Tumor